Abstract
N-of-1 trials are multi-cycle within-patient, randomized, double-blind, cross-over comparisons of a drug and placebo (or another drug) using standardized measures of effect. They provide evidence-based information on individual response to treatment and can be used to optimize the chronic disease management of the individual.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kravitz RL, Duan N (eds) and the DEcIDE Methods Center N-of-1 Guidance Panel (Duan N, Eslick I, Gabler NB, Kaplan HC, Kravitz RL, Larson EB, Pace WD, Schmid CH, Sim I, Vohra S). Design and implementation of N-of-1 trials: a user’s guide. AHRQ Publication No. 13(14)-EHC122-EF. Agency for Healthcare Research and Quality, Rockville, February 2014. www.effectivehealthcare.ahrq.gov/N-1-Trials.cfm
Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ (2011) The N-of-1 clinical trial: the ultimate strategy for individualizing medicine? Pers Med 8(2):161–173
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Nikles, J., Mitchell, G. (2015). Introduction. In: Nikles, J., Mitchell, G. (eds) The Essential Guide to N-of-1 Trials in Health. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7200-6_1
Download citation
DOI: https://doi.org/10.1007/978-94-017-7200-6_1
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-7199-3
Online ISBN: 978-94-017-7200-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)